Answers are grounded in this paper and cite their sources.
Memantine, a non-competitive N-methyl-D-Aspartate (NMDA) receptor antagonist, is currently the only drug proposed for the treatment of moderate to severe Alzheimer’s Disease (AD) [1]. It has been shown to have neuroprotective effects by inhibiting the excitotoxic effect of NMDA glutamate receptors [2]. Memantine has a tolerability profile similar to placebo [1]. However, the worsening of psychotic symptoms in patients with Lewy bodies dementia (LBD) treated with memantine has been recently reported [3].We describe three patients with probable AD who developed worsening or de novo visual hallucinations (VHs) and agitation after memantine treatment.
No takes yet. Share an insight, caveat, or question.
Monastero et al. (2006) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: